Skip to main content
. 2022 Oct 17;5(6):e892. doi: 10.1002/hsr2.892

Figure 1.

Figure 1

PRISMA flowchart of included studies for determining the effect of SSRI/SNRI on clinical outcomes of COVID‐19 patients. COVID‐19, coronavirus disease 2019; PRISMA, Preferred Reporting Items for Systematic reviews and Meta‐Analyses; SNRI, serotonin‐norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor